<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630613</url>
  </required_header>
  <id_info>
    <org_study_id>18-000637</org_study_id>
    <nct_id>NCT04630613</nct_id>
  </id_info>
  <brief_title>NOX4 and Related Biomarkers in ADPKD</brief_title>
  <official_title>NOX4, Mitochondria and Related Biomarkers in Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Polycystic Kidney Disease Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the value of NOX4, markers of mitochondria injury and function, and oxidative&#xD;
      stress as real-time biomarkers to assess disease severity in patients with early autosomal&#xD;
      dominant polycystic kidney disease (ADPKD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a cross sectional study and will include male and female, young (18-40-years)&#xD;
      well characterized patients with early (eGFR&gt;90mL/min/1.73m2) ADPKD. Patients with different&#xD;
      classes of disease severity will be selected using the ADPKD imaging classification. The&#xD;
      study will include 60 class-1 (A-E) patients (N=12 per each sub-class).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>NOX4 levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Determination of NOX4 levels from urine and plasma samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mtDNA copy number</measure>
    <time_frame>Baseline</time_frame>
    <description>Determination of mtDNA copy number from urine and plasma samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tricarboxylic Acid (TCA) cycle metabolites</measure>
    <time_frame>Baseline</time_frame>
    <description>Determination of TCA cycle metabolite concentration from urine and plasma samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>REDOX status</measure>
    <time_frame>Baseline</time_frame>
    <description>Determination of REDOX from urine and plasma samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total kidney volume (TKV)</measure>
    <time_frame>Baseline</time_frame>
    <description>Determined by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Baseline</time_frame>
    <description>Estimated by CKD-epi equation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Patients with a previous diagnosis of ADPKD</arm_group_label>
    <description>Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine and plasma samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients with a previous diagnosis of ADPKD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ADPKD (based on Ravine et al. criteria)&#xD;
&#xD;
          -  Class 1 A-E according to imaging classification&#xD;
&#xD;
          -  Male and female subjects 18 - 40 years of age&#xD;
&#xD;
          -  Estimated GFR&gt; 90 mL/min/1.73 m2 (CKD-EPI)&#xD;
&#xD;
          -  Ability to provide written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Class 2 according to imaging classification&#xD;
&#xD;
          -  Concomitant systemic disease affecting the kidney&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Predicted urine protein excretion in &gt;1 g/24 hrs&#xD;
&#xD;
          -  Use of antioxidants i.e. vitamins, Nrf2 activators&#xD;
&#xD;
          -  Abnormal urinalysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Maria V Irazabal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen R Leistikow, ACRC</last_name>
      <phone>507-266-1316</phone>
      <email>leistikow.kathleen@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Charles D Madsen, CCRP</last_name>
      <phone>507-266-9391</phone>
      <email>madsen.charles@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Maria V Irazabal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Maria V. Irazabal Mira</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Oxidative Stress</keyword>
  <keyword>Mitochondria injury and function</keyword>
  <keyword>NADPH oxidase 4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

